Drugs / ASP8731
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05167526 | Mar → Nov 2022 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-12-01 | Astellas Pharma Inc | Results Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia – from Diagnosis to Relapse – at 2021 American Society of Hematology Annual Meeting astellas.com ↗
The data show potential to increase expression of antioxidant and HbF genes and reduce SCD-related pathophysiology. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-01 | Astellas Pharma Inc | Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia – from Diagnosis to Relapse – at 2021 American Society of Hematology Annual Meeting astellas.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP8731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05167526 ↗ |
| Route | Oral | “Oral” NCT05167526 ↗ |